Beam Therapeutics

BEAM63

$25.05arrow_drop_up6.23%$1.47

BEAM63

$25.05

arrow_drop_up6.23%$1.47

Performance History

Key Stats
Open	$24.53
Prev. Close	$24.49
EPS	-1.58
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	23.59	25.04
52 Week Range	16.95	49.50

Ratios







EPS	-1.58

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Beam Therapeutics (BEAM)

Beam Therapeutics Inc (BEAM) is a leading biotechnology company focused on developing precision genetic medicines using its proprietary base editing technology. The company's mission is to provide innovative solutions to treat genetic diseases and address unmet medical needs. With its cutting-edge platform, Beam Therapeutics is revolutionizing the field of gene editing and has the potential to transform the lives of patients worldwide.

BEAM's stock price history has experienced significant growth since its initial public offering (IPO) in 2020. The company's stock has steadily increased, reflecting the market's confidence in its technology and potential. Investors have been optimistic about the prospects of Beam Therapeutics, driving its stock price higher.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. John M. Evans M.B.A.
Headquarters: Cambridge
Employees: 532
Exchange: NASDAQ

Keep an eye on Beam Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Beam Therapeutics 's (BEAM) price per share?

The current price per share for Beam Therapeutics (BEAM) is $25.05. The stock has seen a price change of $1.47 recently, indicating a 6.23% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Beam Therapeutics (BEAM)?

For Beam Therapeutics (BEAM), the 52-week high is $49.5, which is 97.6% from the current price. The 52-week low is $16.95, the current price is 47.79% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Beam Therapeutics (BEAM) a growth stock?

Beam Therapeutics (BEAM) has shown an average price growth of -6.03% over the past three years. It has received a score of 13 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Beam Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Beam Therapeutics (BEAM) stock price performance year to date (YTD)?

As of the latest data, Beam Therapeutics (BEAM) has a year-to-date price change of -8.61%. Over the past month, the stock has experienced a price change of 8.21%. Over the last three months, the change has been -1.73%. Over the past six months, the figure is 1.01%.

help

Is Beam Therapeutics (BEAM) a profitable company?

Beam Therapeutics (BEAM) has a net income of -$132.53M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -746.4% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $377.71M, although specific revenue growth data is currently not available. Operating income is noted at -$176.48M. Furthermore, the EBITDA is -$160.83M.

help

What is the market capitalization of Beam Therapeutics (BEAM)?

Beam Therapeutics (BEAM) has a market capitalization of $2.02B. The average daily trading volume is 24.78, indicating the stock's liquidity and investor engagement.